A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Status:
Withdrawn
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Dasatinib and lenalidomide are both prescribed for use in patients with different cancers of
the blood. This study is experimental because neither drug has been approved by the Food and
Drug Administration for the treatment of chronic lymphocytic leukemia. There are few standard
treatments when fludarabine is no longer effective in patients with CLL. Some patients have
received additional combination therapy with fludarabine, Campath, bone marrow transplants or
supportive care. Dasatinib and lenalidomide have been effective in high-risk CLL patients in
other pilot mono therapy studies. The combination of dasatinib and lenalidomide has not been
studied in humans before and this study is designed to test whether this combination is safe
to use.